Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. GOOGL
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
(NASDAQ: ABVX) Delayed: 101.66 +2.51 (2.53%)
Previous Close $99.15    52 Week High $ 
Open $99.10    52 Week Low $ 
Day High $103.83    P/E N/A 
Day Low $97.50    EPS $ 
Volume 2,237,680       

(NASDAQ: ABVX) Delayed: 101.66 +2.51 (2.53%)
Previous Close $99.15    52 Week High $ 
Open $99.10    52 Week Low $ 
Day High $103.83    P/E N/A 
Day Low $97.50    EPS $ 
Volume 2,237,680